Boris Shor

发表

Monoclonal antibody-based therapies in cancer: advances and challenges.

P. Sapra, Boris Shor, 2013, Pharmacology & therapeutics.

Targeting mTOR globally in cancer: Thinking beyond rapamycin

R. Abraham, J. Gibbons, Ker Yu, 2009, Cell cycle.

Identification and characterization of a constitutively T-loop phosphorylated and active recombinant S6K1: expression, purification, and enzymatic studies in a high capacity non-radioactive TR-FRET Lance assay.

Wei-guo Zhang, Ker Yu, Boris Shor, 2006, Protein expression and purification.

Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.

Kevin Curran, Judy Lucas, John Ellingboe, 2009, Cancer research.

Cpc2, a Fission Yeast Homologue of Mammalian RACK1 Protein, Interacts with Ran1 (Pat1) Kinase To Regulate Cell Cycle Progression and Meiotic Development

M. McLeod, Wei Wang, Boris Shor, 2000, Molecular and Cellular Biology.

A kinase-dead knock-in mutation in mTOR leads to early embryonic lethality and is dispensable for the immune system in heterozygous mice

Crafford A. Harris, D. Cavender, Boris Shor, 2009, BMC Immunology.

Lysosomes and Antibody–Drug Conjugates

P. Sapra, Maureen M. Dougher, M. Sung, 2016 .

Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin

T. R. Johnson, P. Jasper, J. Tolsma, 2016, The AAPS Journal.

Synthesis and anti-mitotic activity of 6,7-dihydro-4H-isothiazolo[4,5-b]pyridin-5-ones: In vivo and cell-based studies.

M. Krayushkin, A. Kiselyov, V. Semenov, 2017, European journal of medicinal chemistry.

Cytotoxic Spliceostatins from Burkholderia sp. and Their Semisynthetic Analogues.

F. Loganzo, C. J. O’Donnell, F. Koehn, 2014, Journal of natural products.

Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.

R. Abraham, J. Gibbons, L. Toral-Barza, 2010, Cancer research.

Cpc2/RACK1 Is a Ribosome-associated Protein That Promotes Efficient Translation in Schizosaccharomyces pombe*

M. McLeod, J. Calaycay, J. Rushbrook, 2003, Journal of Biological Chemistry.

Requirement of the mTOR Kinase for the Regulation of Maf1 Phosphorylation and Control of RNA Polymerase III-dependent Transcription in Cancer Cells

M. Follettie, L. Toral-Barza, Jiang Wu, 2010, The Journal of Biological Chemistry.

A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis.

R. Abraham, J. Gibbons, L. Toral-Barza, 2008, Cancer research.

Enhanced Antitumor Activity of an Anti-5T4 Antibody–Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes

E. Melamud, E. Rosfjord, P. Sapra, 2015, Clinical Cancer Research.

Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies.

H. Gerber, P. Sapra, Boris Shor, 2015, Molecular immunology.

The BCG Vaccine for COVID-19: First Verdict and Future Directions

J. Ochando, Estanislao Nistal-Villán, Boris Shor, 2021, Frontiers in Immunology.

Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.

R. Abraham, J. Gibbons, J. Lucas, 2009, Cancer Research.

A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis.

R. Abraham, J. Gibbons, Ker Yu, 2008, Cancer research.

Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin

T. R. Johnson, P. Jasper, J. Tolsma, 2016, The AAPS Journal.